Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 TrialShengxiang Ren, Caicun Zhou, Wenxiu Yao et al.|Journal of Thoracic Oncology|2021Cited by 311
miR-548d-3p inhibits osteosarcoma by downregulating KRASJianhua Chen, Quan Yuan, Chongnan Yan et al.|Aging|2019Cited by 28
Knockdown of pyruvate kinase type M2 suppresses tumor survival and invasion in osteosarcoma cells both in vitro and in vivoQuan Yuan, Li Sun, Honghao Yu et al.|Experimental Cell Research|2017Cited by 21
ADAM10 promotes cell growth, migration, and invasion in osteosarcoma via regulating E-cadherin/β-catenin signaling pathway and is regulated by miR-122-5pQuan Yuan, Li Sun, Honghao Yu et al.|Cancer Cell International|2020Cited by 19
<p>Antitumor Effect of miR-1294/Pyruvate Kinase M2 Signaling Cascade in Osteosarcoma Cells</p>Quan Yuan, Li Sun, Honghao Yu et al.|OncoTargets and Therapy|2020Cited by 13